Newly Diagnosed With Bladder Cancer: First Steps

Almost everything about your plan turns on a single fact. Has the tumor reached the muscle layer of the bladder wall?

NCI's staging definitions draw the line clearly.

• Ta is noninvasive papillary carcinoma, a growth on a stalk that has not invaded.
• Tis is carcinoma in situ, a flat tumor confined to the surface layer.
• T1 invades the lamina propria. That is the thin layer just under the lining. This still counts as non-muscle-invasive.
• T2 invades the muscularis propria, the true muscle coat. That is muscle-invasive disease.
• T3 and T4 extend beyond the bladder wall.

Ta, Tis, and T1 are handled one way. T2 and above are handled another way. Ask which group you are in before anything else.

The headline count belongs to the American Cancer Society, which projects 84,530 new cases in the United States and 17,870 deaths for 2026. Bladder cancer ranks sixth overall here. It is fourth in men and twelfth in women.

Hematuria means blood in the urine. It is the main first symptom. It is often painless, and it can come and go. That is why some people delay.

Cystoscopy is the gold standard test. A thin scope passes through the urethra. The urologist then sees the bladder lining directly.

TURBT stands for transurethral resection of bladder tumor. It removes visible tumor through the urethra, with no outside cut. NCI describes resection with fulguration. That means burning the base to stop bleeding and kill remaining cells.

It is also the staging procedure. The tissue removed is what the pathologist reads to assign Ta, Tis, T1, or T2.

That makes one question worth asking outright. Was muscle present in the specimen? T2 is defined by invasion into the muscularis propria. A sample with no muscle in it cannot settle the question that matters most.

NCI also describes giving chemotherapy right after resection in non-muscle-invasive disease. The word for it is intravesical. That means placed directly into the bladder.

After resection, NCI describes risk-based follow-up. Your risk group sets the path. That means watching alone, BCG therapy, or more intravesical chemotherapy.

BCG stands for bacillus Calmette-Guerin. NCI classes it as an intravesical immunotherapy. It is a weakened germ. It stirs an immune reaction inside the bladder.

ACS describes the schedule. Induction runs weekly for about 6 weeks in intermediate-risk and high-risk cancers. Maintenance then continues less often. It runs about a year for intermediate risk, and up to 3 years for high risk.

Side effects follow a pattern. ACS lists flu-like symptoms after a treatment. Those are fever, aches, chills, and fatigue, usually lasting 2 to 3 days. Burning in the bladder, frequent urination, and blood in the urine are common too. Serious infection is rare. The risk is higher in people whose immune systems are suppressed.

The drugs given this way have their own names. ACS lists gemcitabine, mitomycin, valrubicin, epirubicin, and docetaxel. All go in through a urinary catheter.

NCI names three approaches for muscle-invasive disease.

Cisplatin-based chemotherapy first, then radical cystectomy. Treatment given before surgery is called neoadjuvant. Radical cystectomy removes the bladder.

Trimodality bladder preservation. This pairs radiation with chemotherapy at the same time. It follows the fullest resection possible. The goal is to keep the bladder.

Radical cystectomy alone.

If the bladder is removed, urine needs a new route. NCI calls this urinary diversion. It creates another way for the body to store and pass urine. It may use a segment of colon, catheters, or an opening in the abdomen with an outside bag.

Ask which type of diversion is planned, and ask to speak with a wound and ostomy nurse before surgery, not after.

This is why surveillance is close and long. NCI says the entire urothelium must be checked once a tumor is found. The urothelium is the lining that runs through the kidneys, ureters, bladder, and urethra.

Bladder cancer is often multifocal, meaning it starts in more than one site. It arises from a field defect. That means the whole lining met the same damage. A clean cystoscopy today does not end follow-up.

NCI reports that cigarette smoking causes up to one-half of all bladder cancers. Other listed risks include job exposure to dyes, metals, and petroleum products. Past treatment with cyclophosphamide counts, as does past pelvic radiation. So do chronic infections, including parasites.

Quitting matters after diagnosis, not only before it. Ask for a referral to a tobacco cessation program at the same visit where treatment is planned.

NCI names four immunotherapy drugs used in bladder cancer. They are atezolizumab, avelumab, nivolumab, and pembrolizumab. It names four targeted drugs too. They are enfortumab vedotin, erdafitinib, ramucirumab, and sacituzumab govitecan.

Erdafitinib depends on a specific finding, so ask whether FGFR testing has been done if advanced disease is being discussed.

• Call 911 or go to an emergency department if you cannot pass any urine at all and your lower abdomen is painful and swollen. A fully blocked bladder is an emergency and needs a catheter.
• Call 911 or go to an emergency department if heavy bleeding fills the stream with clots, or you feel faint, cold, or your heart is racing alongside it.
• Phone your care team without delay, at any hour, if a thermometer reads 100.4°F (38°C) or higher during treatment. NCI describes infection during cancer treatment as life threatening and needing urgent care, and asks you to call before reaching for anything that lowers a temperature, since that can mask how ill you are. Should you not reach anyone quickly, go to an emergency department and say at the desk that you are in cancer treatment.
• Call your care team the same day if the flu-like reaction after a BCG instillation runs past the usual 2 to 3 days ACS describes, or arrives as a high fever with shaking chills. A BCG infection that has spread beyond the bladder is treated differently from a sore bladder.
• Call your care team the same day if pain settles in your flank, the area below the ribs at the back, together with fever. That can mean infection has travelled above the bladder.
• Call your care team within a day or two if burning and frequency after an instillation are not easing, or if a urostomy or catheter is leaking, sore, or blocked.

• Is my cancer non-muscle-invasive or muscle-invasive?
• Was muscle present in my TURBT specimen?
• Is the tumor low grade or high grade, and is carcinoma in situ present?
• What risk group am I in, and does that mean surveillance, BCG, or intravesical chemotherapy?
• If BCG is planned, how many weeks of induction and how long of maintenance?
• If cystectomy is being discussed, is chemotherapy planned before surgery?
• What is my cystoscopy surveillance schedule for the next two years?

For related reading, see Cancer Staging, Pathology Reports, and Getting a Second Opinion.

• National Cancer Institute — Bladder Cancer Treatment (PDQ), Health Professional Version
• National Cancer Institute — Bladder Cancer Treatment (PDQ), Patient Version
• American Cancer Society — Cancer Facts & Statistics
• American Cancer Society — Intravesical Therapy for Bladder Cancer
• National Cancer Institute — Infection and Neutropenia during Cancer Treatment